Mind-altering drugs like LSD, ketamine or magic mushrooms could be combined with psychotherapy to treat people suffering from depression, compulsive disorders or chronic pain, Swiss scientists suggested on Wednesday.

Research into the effects of psychedelics, used in the past in psychiatry, has been restricted in recent decades because of the negative connotations of drugs, but the scientists said more studies into their clinical potential were now justified.

msnbc.msn.com

An international conference offering continuing medical education (CME) credits.
Open to physicians, healthcare professionals, and the general public

Featuring dozens of world-renowned presenters including:

Stanislav Grof, M.D., co-founder of transpersonal psychology
Michael Mithoefer, M.D., Principal Investigator for MAPS Flagship US MDMA/PTSD Study
Alex and Allyson Grey, visionary artists
Andrew Weil, M.D., integrative medicine proponent (by video)
David Nichols, Ph.D., medicinal chemist and pharmacologist
Charles Grob, M.D., UCLA psilocybin researcher
Roland Grifiths, M.D., Johns Hopkins psilocybin researcher
Ralph Metzner, Ph.D., consciousness researcher and psychotherapist
Earth and Fire Erowid, founders of Erowid.org
Rick Doblin, Ph.D., founder and executive director of MAPS

And dozens of other experts discussing ayahuasca, ibogaine, LSD, MDMA, psilocybin, and salvia divinorum.

Plus a special banquet to honor the lifetime of achievements of psychedelic luminaries Sasha and Ann Shulgin.

maps.org